Tesamorelin + Ipamorelin Blend Enhanced GH Release Results Timeline Expect: Full Comparison
The table below contrasts the tesamorelin + ipamorelin blend timeline against single-agent protocols and exogenous recombinant GH. Tesamorelin + Ipamorelin Blend 8–15 (60–90 min post-injection) Week 2–3 (15–25% above baseline) 1.4–2.1 kg Week 4–6 (subcutaneous
This comparison does not assign a generated winner or score.
- The table below contrasts the tesamorelin + ipamorelin blend timeline against single-agent protocols and exogenous recombinant GH.
- Tesamorelin + Ipamorelin Blend
- 8–15 (60–90 min post-injection)
- Week 2–3 (15–25% above baseline)
- 1.4–2.1 kg
- Week 4–6 (subcutaneous fat reduction)
- Dual-pathway stimulation produces higher peak GH and faster IGF-1 response than single agents. Ideal for time-sensitive research protocols requiring measurable tissue effects within 8–12 weeks
- Tesamorelin Monotherapy
- 5–9 (90–120 min post-injection)
- Week 3–4 (12–18% above baseline)
- 1.0–1.4 kg
- Week 6–8
- GHRH analog alone produces moderate GH elevation. Adequate for long-term metabolic studies but slower tissue response than combined protocols
- Ipamorelin Monotherapy
- 4–7 (60 min post-injection)
- Week 4–5 (10–15% above baseline)
- 0.8–1.2 kg
- Week 8–10
- Secretagogue-only protocols lack the GH synthesis upregulation that GHRH provides. Lower peak GH and delayed IGF-1 rise limit short-term tissue outcomes
- Recombinant GH (Exogenous)
- Continuous elevation (5–12 ng/mL)
- Immediate (IGF-1 rises within 48–72 hours)
- 2.0–3.5 kg
- Week 2–4
- Exogenous GH bypasses endogenous regulation entirely. Faster tissue effects but higher receptor downregulation risk and no preservation of natural pulsatile secretion
- MK-677 (Oral Ghrelin Mimetic)
- 3–6 (sustained elevation 12–24 hours)
- Week 3–4 (10–18% above baseline)
- 1.2–1.8 kg
- Oral bioavailability and sustained GH elevation avoid injection protocols, but ghrelin pathway cross-reactivity causes appetite stimulation and water retention in 40–50% of subjects